IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $213.000 thousand which missed the analyst consensus estimate of $325.000 thousand by 34.46 percent. This is a 17.12 percent decrease over sales of $257.000 thousand the same period last year.